Conference Day Two

8:00 am Coffee & Networking

8:55 am Chairman’s Opening Remarks

Targeting the RAS/MAPK Signalling Pathway

9:00 am Targeting RAF Kinases


  • Describing the role of RAF Kinases and their link with ERK
  • Illustrating how targeting RAF presents a therapeutic opportunity

9:30 am Sourcing the Immune System to Induce Immunogenic Cell Death In Kras-Colorectal Cancer Cells


  • Review how current approaches aimed at inducing immunogenic cell death (ICD) to incite an immune response against cancer neoantigens are based on the use of chemotherapeutics and other agents
  • Results are hampered by issues of efficacy, combinatorial approaches, dosing and toxicity. Here, we adopted a strategy based on the use of an immunomolecule that overcomes pharmachemical limitations.
  • Cytofluorometry, electron microscopy, RT-PCR, western blotting, apotome immunofluorescence, MLR and xenografts

10:00 am Presentation From Our Innovation Partner, Enzymlogic



10:10 am Morning Networking Break

11:00 am Targeting Oncogenic KRAS-G12D Mutation Employing Engineered Exosomes in Pancreatic Cancer

  • Raghu Kalluri Professor- Cancer Biology, University Texas MD Anderson Center


  • Direct inhibitors do not exist for KRAS-G12D
  • We engineered exosomes to deliver siRNA specific to Kras-G12D (iExosomes). The iExosomes target pancreatic cancer cells to suppress tumor growth and increase the overall survival of mice with PDAC
  • Preclinical studies, GLP-toxicology studies, clinical grade GMP production and FDA IND filing led to a Phase I clinical trial in PDAC

11:30 am Tumor-Selective Targeting of Kinase Conformations For Cancer Therapy

  • Poulikos Poulikakos Associate Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai


  • Therapeutic effectiveness of targeted cancer therapies is limited by Incomplete inhibition of the target pathway in the tumor caused by various adaptive resistance mechanisms
  • Increased drug dosing or vertical drug combinations to overcome resistance are limited by on-target toxicities in normal tissue and low Therapeutic Index
  • Improved therapies require drugs and drug combinations that target tumor-selective kinase conformations to achieve both potent antitumor efficacy and a high Therapeutic Index

Improving Response Rates Through Well-Tested, Powerful Combination Therapies

12:00 pm Rationalizing Kinase Inhibitor Combinations with Immunotherapy to Optimize Tumor Killing


  • Harnessing the patients’ immune systems with novel kinase inhibitors to minimize side effects
  • Assessing the key take-aways from PI3K-PD-1 dual blockade to expand to other kinase inhibitors and checkpoint inhibitors
  • Theorizing the potential for novel kinase inhibitors to act on checkpoint

12:30 pm Lunch & Networking

1:30 pm Lymphatropic Combination Therapy

  • Brian Ross Professor of Biological Chemistry Director, Center for Molecular Imaging, University of Michigan


  • Targeting MAPK and PI3K/mTOR pathways is critical due to crosstalk
  • Combination therapy strategies have been hampered by dose-limiting toxicities
  • A Lymphatropic single agent orally bioavailable mutikinase inhibitor provides a path forward

2:00 pm Maximizing the Value of Your Therapeutic

  • Terri-Anne Cock Head of Translational Biology, Amplia Therapeutics Limited


  • Discuss Amplia’s FAK problem and the diversity of conditions it has been applied in
  • Explore the rationale that led to the rapid expansion across this multitude of domains
  • Look at what the future of these programs looks like

2:30 pm Utilizing a Multikinase Approach


  • Harnessing multikinase inhibitors to target multiple cancer indications
  • Discussing the potential to treat multiple cancer indications by targeting multiple MOAs with multi-kinases
  • Exploring research methods to improve mutational specificity and prevent acquired resistance

3:00 pm Afternoon Refreshments & Networking

Targeting Established Pharmacological Mechanisms in Alternative Indications Beyond Oncology to Meet Unmet Needs

3:30 pm Novel Potential Applications of Kinase Activators And Inhibitors In Neurological Conditions


  • The interplay between potassium channels and protein kinases appears to play important roles in physiology and disease
  • otassium channels can lead to activation and/or inhibition of kinases
  • The talk will explore potassium channels-kinases interactions in mouse models of dementia and developmental and epileptic encephalopathies

4:00 pm Virtual: Implementation of Kinase Inhibitors in Dermatology for Non-Oncological Disorders – Treatment for Alopecia Areata to Vitiligo: JAK Inhibitors & The Golden Age of Dermatology

  • Brett King Associate Professor of Dermatology, Yale University School of Medicine


  • Describing the broad utility of JAK inhibitors across dermatological diseases, including alopecia areata, atopic dermatitis, dermatomyositis, granuloma annulare and sarcoidosis, lichen planus, morphea, psoriasis, and vitiligo
  • Identifying challenges of clinical trials in dermatological orphan diseases

4:30 pm Chairman’s Closing Remarks

End of Summit